AKR1C3 is overexpressed in acute myeloid leukemia and T-cell acute lymphoblastic leukemia and confers chemotherapeutic resistance to anthracycline, which is the first-line agent for leukemia treatment (24). Here, AKR1C3 is linked to leukemia.